Nanoform Interim Report January - September 2021 - Seite 2

- In February, a PoC agreement was signed with an East Coast US Biotech Company.

- In February, Nanoform announced further positive interim results from its clinical study. The fast absorption data from the second part of the study implied that nanoforming might offer viable alternatives to complex formulation approaches such as cyclodextrin based technologies.

- In February, Nanoform appointed Dr Jamie Unwin as Commercial Insights Officer, based in Oxford UK, starting in April.

- On February 26, a new near-term business target was announced: "At least three new non-GMP lines in 2021 and two new GMP lines in 2022".

- In March, Nanoform and Nacuity Pharmaceuticals, a Texas-based clinical stage pharmaceutical company, signed a technology Proof of Concept agreement to enhance ophthalmic drug delivery of Nacuity's NPI-001 and NPI-002 drug candidates.

- In March, a PoC agreement was signed with a European Biotech Company.

- In March, Nanoform launched the next generation of its STARMAP artificial intelligence platform, v2.0. The technology utilizes sparse-data AI to augment experimental results from its CESS nanoparticle engineering process with detailed expert knowledge, allowing reliable predictions to be made regarding partners' potential success of nanoforming their drug molecules. STARMAP is a digital version of the CESS technology that enables in silico experiments in large quantities, creating fast predictions of which molecules should be nanoformed.

- In March, EUR 40 million (gross) was raised in a successful new share issue through an accelerated bookbuilding process. The considerably oversubscribed capital raise attracted strong interest from Nordic and international investors, including a considerable number of large global Tier 1 institutional investors.

- In March, Nanoform appointed Dr Christopher Worral as VP Business Development US, based in San Diego, starting in May.

- During 1-3/2021 three new non-GMP lines were commissioned. As a result, the near-term business target "at least three new non-GMP lines in 2021", was achieved.

- On April 6, at the AGM, the Board of Directors, chaired by Miguel Calado, was re-elected.

- In April, Nanoform and Aprecia, a US-based three-dimensional printing pharmaceutical company, announced that they are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms. The collaboration targets to combine Nanoform's fast dissolution nanoformed particles with Aprecia's ZipDose-technology platform for rapid disintegration to enable high performance buccal and oral delivery of medicines to patients where rapid absorption is essential.